Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Trial Profile

Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Cisplatin; Docetaxel
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 12 Apr 2016 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016.
    • 02 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top